Free Trial
NASDAQ:MNOV

MediciNova (MNOV) Stock Price, News & Analysis

MediciNova logo
$2.13 +0.13 (+6.50%)
(As of 11/22/2024 ET)

About MediciNova Stock (NASDAQ:MNOV)

Key Stats

Today's Range
$1.93
$2.13
50-Day Range
$1.53
$2.28
52-Week Range
$1.12
$2.55
Volume
63,109 shs
Average Volume
149,157 shs
Market Capitalization
$104.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

MediciNova Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

MNOV MarketRank™: 

MediciNova scored higher than 14% of companies evaluated by MarketBeat, and ranked 901st out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for MediciNova.

  • Earnings Growth

    Earnings for MediciNova are expected to decrease in the coming year, from ($0.23) to ($0.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MediciNova is -10.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MediciNova is -10.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MediciNova has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.39% of the float of MediciNova has been sold short.
  • Short Interest Ratio / Days to Cover

    MediciNova has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in MediciNova has recently decreased by 8.07%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MediciNova does not currently pay a dividend.

  • Dividend Growth

    MediciNova does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.39% of the float of MediciNova has been sold short.
  • Short Interest Ratio / Days to Cover

    MediciNova has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in MediciNova has recently decreased by 8.07%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    MediciNova has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for MediciNova this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MediciNova insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.90% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 9.90% of the stock of MediciNova is held by institutions.

  • Read more about MediciNova's insider trading history.
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com
Trump Wins… But Elon Says Get Ready to Brace
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
MediciNova provides update in letter to stockholders
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)
MediciNova granted Notice of Allowance for MN-001 patent by USPTO
See More Headlines

MNOV Stock Analysis - Frequently Asked Questions

MediciNova's stock was trading at $1.50 at the beginning of 2024. Since then, MNOV shares have increased by 42.0% and is now trading at $2.13.
View the best growth stocks for 2024 here
.

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01.

Top institutional shareholders of MediciNova include Geode Capital Management LLC (1.03%), Charles Schwab Investment Management Inc. (0.15%) and Jane Street Group LLC (0.03%).
View institutional ownership trends
.

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Inuvo (INUV).

Company Calendar

Last Earnings
8/09/2023
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MNOV
Employees
10
Year Founded
2000

Profitability

Net Income
$-8,560,000.00
Pretax Margin
-816.10%

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
$1.12 per share

Miscellaneous

Free Float
41,738,000
Market Cap
$104.48 million
Optionable
Optionable
Beta
0.77

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:MNOV) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners